Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Investing Activities (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Cash from Investing Activities data on record, last reported at $51.5 million in Q4 2023.

  • For Q4 2023, Cash from Investing Activities rose 279.9% year-over-year to $51.5 million; the TTM value through Dec 2023 reached $35.8 million, down 85.62%, while the annual FY2025 figure was $180.0 million, 232.04% up from the prior year.
  • Cash from Investing Activities reached $51.5 million in Q4 2023 per CGEM's latest filing, up from -$43.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $300.9 million in Q2 2022 and bottomed at -$154.6 million in Q2 2021.
  • Average Cash from Investing Activities over 4 years is -$3.4 million, with a median of -$8.9 million recorded in 2020.
  • Peak YoY movement for Cash from Investing Activities: plummeted 1391.4% in 2021, then surged 294.61% in 2022.
  • A 4-year view of Cash from Investing Activities shows it stood at $11.4 million in 2020, then tumbled by 238.65% to -$15.9 million in 2021, then tumbled by 80.37% to -$28.6 million in 2022, then soared by 279.9% to $51.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $51.5 million in Q4 2023, -$43.0 million in Q3 2023, and $12.1 million in Q2 2023.